BONESUPPORT™ To Present Corporate Overview At Stifel 2015 Healthcare Conference

USA - English

• USA - Deutsch
• USA - español
• USA - Français

LUND, Sweden, Nov. 13, 2015 /PRNewswire/ -- BONESUPPORT™, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced that Lloyd Diamond, CEO of BONESUPPORT™, will provide a corporate overview at the Stifel 2015 Healthcare Conference in New York, NY, on November 18, 2015.  The presentation will be audio-webcast live and archived for replay following the conference.

Stifel 2015 Healthcare Conference Presentation
Date:             Wednesday, November 18, 2015
Time:             4:30 pm Eastern Time
Location:        New York, NY - The New York Palace Hotel, Henry Room
Webcast:       http://www.veracast.com/webcasts/stifel/healthcare2015/97212649653.cfm 

About BONESUPPORT™
BONESUPPORT™ is an emerging leader of injectable bone graft substitutes for orthopedics, and trauma focusing on bone infection, instrument augmentation and spinal applications. CERAMENT™ is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery. CERAMENT™|G and CERAMENT™|V are the first CE-marked injectable antibiotic eluting ceramic bone graft substitutes indicated to promote and protect bone healing in the management of osteomyelitis, (bone infections). CERAMENT's unique biologic properties deliver a consistent, pre-packed and ready-to-use formulation to facilitate optimal delivery. CERAMENT™|G and CERAMENT™|V are not available in the United States.

CERAMENT™ is a fully developed product platform that is commercially available in the U.S., Europe, SE Asia and the Middle East. CERAMENT™ is revolutionizing the treatment of fragility and other fractures caused by disease and trauma. Scientific research of CERAMENT™ spans more than eleven years. Over fifty pre-clinical, clinical and animal studies have been conducted and more than 20,000 patients have been treated with CERAMENT™.  The company was founded in 1999 and is based in Lund, Sweden with subsidiary locations in the US and Germany. To learn more about BONESUPPORT™ please visit www.bonesupport.com.

Press Inquiries:
Offer Nonhoff
Chief Financial Officer
[email protected]
Phone +46 46 286 53 60

PR 0480-01 en

SOURCE BONESUPPORT

Related Links

http://www.bonesupport.com